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Background: A new edition of the TNM was recently released that includes
modifications for the staging system of kidney cancers. Specifically, T2 cancers
were subclassified into T2a and T2b (!10 cm vs >10 cm), tumors with renal vein
involvement or perinephric fat involvement were classified as T3a cancers, and
those with adrenal involvement were classified as T4 cancers.
Objective: Our aim was to validate the recently released edition of the TNM staging
system for primary tumor classification in kidney cancer.
Design, setting, and participants: Our multicenter retrospective study consisted of
5339 patients treated in 16 academic Italian centers.
Intervention: Patients underwent either radical or partial nephrectomy.
Measurements: Univariable and multivariable Cox regression models addressed
cancer-specific survival (CSS) after surgery.
Results and limitations: In the study, 1897 patients (35.5%) were classified as pT1a,
1453 (27%) as pT1b, 437 (8%) as pT2a, 153 (3%) as pT2b, 1059 (20%) as pT3a, 117
1 See appendix.
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1. Introduction
TNM classification is the globally accepted method of
describing the anatomic extent of cancer. In kidney tumors,
the outcome stratification proposed in the sixth edition of
the TNM, published in 2002, was validated in several studies
[1–3]. However, some studies suggested that patients with
localized cancers could be better dichotomized around a
tumor diameter of 5–6 cm [4–7] and that T3a and pT3b
stages were heterogeneous [8]. Consequently, several
proposals for further updates were implemented, both for
localized [9,10] and locally advanced [11–17] disease.
Very recently, the Union Internationale Contre le Cancer
(UICC) and the American Joint Committee on Cancer (AJCC)
released the seventh edition of the staging system, which
took effect on January 1, 2010. In this latest update, some
modifications were made to the staging system for kidney
tumors. In comparison with the sixth edition of TNM, T2
cancers were subclassified into two subgroups based on a
tumor size cut-off point of 10 cm (T2a !10 cm vs T2b
>10 cm). Moreover, tumors with renal vein involvement or
perinephric fat involvement were classified as T3a, whereas
those with adrenal involvement were classified as T4
cancers. All the other categories were unchanged [18].
The purpose of the present study was to validate the
recently released seventh edition of the TNM staging
system for primary tumor classification in kidney tumors
in a multicenter series of patients with renal cell carcinoma
(RCC) treated with radical nephrectomy (RN) or partial
nephrectomy (PN) in 16 academic centers in Italy.
2. Patients and methods
The Surveillance and Treatment Update Renal Neoplasms (SATURN)
project was promoted by LUNA, the Leading Urological No-Profit
Foundation for Advanced Research of the Società Italiana di Urologia
(ie, the Italian Society of Urology). A total of 16 academic centers in Italy
provided data. The database comprised 5893 patients who underwent
RN or PN between 1995 and 2007 because of a suspicion of kidney
cancer. The patients with benign histology (n = 430), those lacking
histologic subtypes of the tumor (n = 85), and those where the
concomitant presence of some adverse pathologic features was not
reported (n = 39) were excluded from the study. The 5339 remaining
patients were the subjects of the present analysis.
The mode of presentation was distinguished according to the Patard
classification [19]. Clinical staging included at least abdominal computed
tomography (CT) scans and chest x-rays. Bone scans and brain CT scans
were obtained only when indicated by signs and symptoms.
Surgery was performed by several surgeons according to the
standard criteria for RN (ie, extrafascial dissection of the kidney). The
hilar and regional lymph nodes adjacent to the ipsilateral great vessel
generally were resected, along with enlarged lymph nodes if they were
abnormal on preoperative CT scans or palpable intraoperatively.
Extended lymphadenectomy was routinely performed in a few centers.
In patients with a contralateral normal kidney, elective PN had been
routinely indicated in the presence of single peripheral tumors !4 cm,
although some referral centers also performed elective PN in the case of
larger tumors.
2.1. Pathologic evaluation
All surgical specimens were processed according to standard pathologic
procedures at each institution. Tumor stage was reassigned according to
the recently released seventh edition of the AJCC-UICC TNM classifica-
tion. Specifically, T2 cancers were subclassified into two subgroups
based on a tumor size cut-off point of 10 cm (T2a !10 cm vs T2b
>10 cm), tumors with renal vein involvement or perinephric fat
involvement were classified as T3a, whereas those with adrenal
involvement were classified as T4 cancers. Classification of T1 tumors,
as well as of those with vena cava thrombus and Gerota fascia invasion,
was unchanged [18].
The Heidelberg and Fuhrman classifications were used to assign
histologic type and nuclear grade, respectively [20,21]. No central
pathologic slide review was performed.
2.2. Follow-up regimen
Patients were generally observed every 3–4 mo for the first year after
surgery, every 6 mo from the second through the fifth years, and
annually thereafter. Follow-up consisted of a history, a physical
examination, routine blood work and serum chemistry studies, chest
radiography, and radiographic evaluation of the contralateral or remnant
kidney. Elective bone scan, chest CT, and magnetic resonance imaging
were performed when clinically indicated.
Cause of death was determined by the treating physicians, by chart
review corroborated by death certificates, or by death certificates alone.
(2%) as pT3b, 26 (0.5%) as pT3c, and 197 (4%) as pT4. At a median follow-up of 42
mo, 786 (15%) had died of disease. In univariable analysis, patients with pT2b and
pT3a tumors had similar CSS, as did patients with pT3c and pT4 tumors. Moreover,
both pT3a and pT3b stages included patients with heterogeneous outcomes. In
multivariable analysis, the novel classification of the primary tumor was a powerful
independent predictor of CSS ( p for trend <0.0001). However, the substratification
of pT1 tumors did not retain an independent predictive role. The major limitations
of the study are retrospective design, lack of central pathologic review, and the
small number of patients included in some substages.
Conclusions: The recently released seventh edition of the primary tumor staging
system for kidney tumors is a powerful predictor of CSS. However, some of the
substages identified by the classification have overlapping prognoses, and other
substages include patients with heterogeneous outcomes. The few modifications
included in this edition may have not resolved the most critical issues in the
previous version.
# 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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2.3. Statistical analysis
Continuous variables were reported as median value and interquartile
ranges (IQRs). The Kaplan-Meier method was used to calculate survival
functions, and differences were assessed with the log-rank statistic.
Univariable and multivariable Cox regression models addressed time to
cancer-specific mortality after surgery. Patients alive and disease free
were censored. Statistical significance in this study was set as p < 0.05.
All reported p values are two sided. Analyses were performed with SPSS
v.16.0 (SPSS Inc, Chicago, IL, USA) by one of the authors (GN).
3. Results
Table 1 summarizes the clinical and pathologic features of
the 5339 analyzed patients. Based on the novel TNM staging
system, 1897 of the patients (35.5%) were classified as pT1a,
1453 (27%) as pT1b, 437 (8%) as pT2a, 153 (3%) as pT2b,
1059 (20%) as pT3a, 117 (2%) as pT3b, 26 (0.5%) as pT3c, and
197 (4%) as pT4.
At a median follow-up of 42 mo (IQR: 24–75 mo), 3949
patients (74%) were alive and disease free, 786 (15%) had
died of disease, and 335 (6%) had died of other causes.
Median follow-up of the 3987 living patients was 48 mo
(IQR: 25–84 mo). The overall 5- and 10-yr cancer-specific
survival (CSS) estimates were 83.2% (standard error [SE]:
0.6%) and 76.6% (SE: 0.9%), respectively.
According to the 2009 TNM staging system, 5-yr CSS was
94.9% (SE: 0.6%) in pT1a, 92.6% (SE: 0.8%) in pT1b, 85.4% (SE:
1.9%) in pT2a, 70% (SE: 4.1%) in pT2b, 64.7% (SE: 1.8%) in
pT3a, 54.7% (SE: 5.9%) in pT3b, 17.9% (SE: 10.1%) in pT3c,
and 27.1% (SE: 4.0%) in pT4 (pooled over strata p < 0.00001)
(Fig. 1). All the pairwise survival differences among the
different pT stages were statistically significant with the
exception of those observed between pT2b and pT3a
cancers (log-rank pairwise p = 0.34) and between pT3c
and pT4 cancers (pairwise p = 0.26). Considering only the
4848 cases with N0/NxM0 disease, the survival differences
between pT1a and pT1b, pT2b and pT3a, pT3a and pT3b, and
pT3c and pT4 were not statistically significant (pairwise p
values >0.05; data not extensively shown).
The pT3a subcategory was composed of 503 cases (47%)
with perinephric fat invasion only, 401 (38%) with renal
vein invasion only, and 155 (15%) with concomitant
perinephric fat and renal vein invasion. Patients with
isolated perinephric fat and renal vein invasion had similar
outcomes (pairwise p = 0.05), but the patients with the two
concomitant features had significantly lower CSS (pairwise
p values <0.0001) (Fig. 2). Considering only the 866 cases
with pT3aN0M0 RCC, patients with renal vein invasion had
the highest CSS, followed by those with only perirenal fat
invasion and by those with the two concomitant features,
with all the survival differences being statistically signifi-
cant (pairwise p values <0.045; data not extensively
shown).
The pT3b subcategory included 69 cases (59%) with
infradiaphragmatic vena caval thrombus only, and 48 cases
(41%) with concomitant infradiaphragmatic vena caval
thrombus and perirenal fat invasion. Those patients with
the two concomitant features had significantly lower CSS
compared with those with thrombus only ( p = 0.0007)
(Fig. 3). Similar statistics were obtained limiting the
analysis to the 84 pT3bN0M0 cases ( p = 0.005).
The pT3c subcategory was composed of 16 patients (61%)
with supradiaphragmatic vena caval thrombus only, and 10
patients (39%) with concomitant supradiaphragmatic
vena caval thrombus and perirenal fat invasion. The
two subgroups of pT3c patients had overlapping CSS
Table 1 – Clinical and pathologic features of the 5339 analyzed
patients
Variables




Mode of presentation, No. (%)*
Incidental 3335 (62)
Local symptoms 1438 (27)
Systemic symptoms 260 (5)
Type of surgery, No. (%)
Radical nephrectomy 3799 (71)
Elective partial nephrectomy 1311 (25)
Imperative partial nephrectomy 229 (4)
Histologic subtype, No. (%)
Clear cell 4334 (81)
Papillary 577 (11)
Chromophobe 291 (6)
Collecting duct 47 (1)
Unclassified 90 (2)
Pathologic tumor size, median (IQR) 5 (3.5–7)






















M stage, No. (%)
M0 5016 (94)
M1 323 (6)





IQR = interquartile range.
* Missing in 306 cases (6%).
** Missing in 395 cases (7%).
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( p = 0.33) (Fig. 4). Similar figures were obtained limiting the
analysis to the 12 pT3cN0M0 cases ( p = 0.135).
Evaluating the prognostic role of the proximal extension
of tumor thrombus with renal or caval veins, all the CSS
differences among the 628 patients with renal vein, 146
with infradiaphragmatic, and 27 with supradiaphragmatic
vena caval thrombus were statistically significant ( p values
<0.009). However, considering only the 405 patients with
N0M0 disease and isolated tumor thrombus in the absence
of other adverse pathologic features, the CSS of those with
renal vein thrombosis and infradiaphragmatic vena caval
thrombus was similar ( p = 0.267). Patients with infradia-
phragmatic or supradiaphragmatic vena caval thrombus
had a similar prognosis ( p = 0.067).
The pT4 subcategory included 68 cases (29%) with tumor
extending beyond the Gerota fascia, 81 cases (41%) with
adrenal gland invasion, and 48 cases (24%) with the two
concomitant features. The three subgroups of pT4 patients
had similar outcomes ( p = 0.32) (Fig. 5). Similar figures
were obtained limiting the analysis to the 97 pT4N0M0
cases ( p values >0.05; data not extensively shown). Table 2
summarizes the data of univariable and multivariable
analyses for CSS.
On multivariable Cox regression analyses, the T stage
according to the 2009 staging system was an independent
predictor of CSS ( p for trend<0.0001), once adjusted for the
effect of all the other covariates. Notably, the substratifica-
tion of T1 tumors was not an independent predictor of
survival in multivariable analysis (hazard ratio [HR]: 1.1;
p = 0.70). Limiting the analysis to N0M0 cases, the 2009 T
stage retained an independent predictor role ( p for trend
[(Fig._1)TD$FIG]
Fig. 1 – Cancer-specific survival (CSS) probability according to the 2009
TNM staging system (log rank pooled over strata p < 0.0001). Five-year
CSS was 94.9% in pT1a (blue curve), 92.6% in pT1b (green curve), 85.4% in
pT2a (gray curve), 70% in pT2b (violet curve), 64.7% in pT3a (yellow
curve), 54.7 in pT3b (red curve), 17.9 in pT3c (light blue curve), and 27.1%
in pT4 (light gray curve). All the pairwise survival differences among the
different pT stages were statistically significant with the exception of
those observed between pT2b and pT3a cancers (log-rank pairwise
p = 0.34) and between pT3c and pT4 cancers (log-rank pairwise p = 0.26).
[(Fig._2)TD$FIG]
Fig. 2 – Cancer-specific survival (CSS) probability within the pT3a
subcategory (log-rank pooled over strata p < 0.0001). Five-year CSS was
75% in patients with renal vein invasion only (blue curve), 66.9% in
patients with perirenal fat invasion only (green curve), and 32.4% in
patients with the two concomitant features (red curve). Renal vein
invasion only versus perirenal fat invasion only: log-rank pairwise
p = 0.05. Concomitant renal vein and perirenal fat invasion versus each
individual features: log-rank pairwise p < 0.0001.
[(Fig._3)TD$FIG]
Fig. 3 – Cancer-specific survival (CSS) probability within the pT3b
subcategory. Five-year CSS was 65.9% in patients with
infradiaphragmatic vena caval thrombus only (blue curve) and 36.5% in
patients with concomitant invasion of the perirenal fat (green curve).
Log-rank pooled over strata p = 0.0007.
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<0.0001). However, pT1b (HR: 0.9; p = 0.463) and pT2a (HR:
1.5; p = 0.77) were not statistically significantly different
from the reference pT1a group (data not extensively
shown).
4. Discussion
We have reported what is to our knowledge the first
attempt to validate the recently released seventh edition of
the TNM staging system for RCC. In the present series, the
novel classification of the primary tumor was a powerful
independent predictor of CSS. However, some of the
substages identified by the classification had overlapping
prognoses (pT2b and pT3a; pT3c and pT4 RCC), whereas
both pT3a and pT3b stages included patients with
heterogeneous outcomes. Lastly, in multivariable analysis,
the substratification of pT1 RCC into pT1a and pT1b did not
retain an independent predictive role for CSS.
The TNM staging system should effectively communi-
cate critical tumor characteristics, aid the clinician in the
appropriate selection of therapeutic options, stratify the
patient’s risk of cancer progression or cancer death, allow
the evaluation of treatment results, make data comparison
from different centers easy, and determine the selection
criteria for clinical trials [22]. To accomplish all these
purposes, in 2002, the UICC introduced a structured process
for regular updates of the TNM classification system [22].
Applying such a process, the seventh edition of the staging
system for RCC introduced a subclassification of T2 into two
subgroups based on a tumor size cut-off point of 10 cm (T2a
!10 cm vs T2b >10 cm) and reclassified direct adrenal
involvement as T4 cancers [18].
Regarding localized RCC, the T2 subclassification was
based on a study from the Mayo Clinic in which the 10-cm
break point was able to stratify T2 patients into two
substages with statistically different survival probabilities,
both better than those observed in pT3a cases [10]. In the
present analysis, the CSS probabilities of pT2b patients were
similar to those of the new pT3a substage. That result might
be due to the small number of patients included in these
subgroups (only 3%), as well as the overall improvement of
the outcomes of the pT3a patients after removal of cases
with direct adrenal involvement, reclassified as pT4 in the
new TNM. On the whole, the modification of RCC primary
tumor classification wound up splitting localized cancers
into four subgroups (T1a vs T1b vs T2a vs T2b) that were
numerically imbalanced, with most of the patients still
classified as T1. Moreover, in terms of clinical staging, the
subclassification of T1 cancers is losing its main clinical
relevance because the indication for elective PN in tumors
has been extended to tumors >4 cm [23,24]. Consequently,
a staging system based on a cut-off point in the range of
5–6 cm might be more suitable from a clinical point of view
to indicate those patients suitable for PN as well as,
according to the available data, to dichotomize the cancer-
related outcome of localized cancers [4–7,9].
With regard to the updates in the staging of locally
advanced RCC, the choice to move direct adrenal invasion
into the pT4 stage was driven by several studies, all of which
demonstrated that tumors with adrenal invasion had the
[(Fig._4)TD$FIG]
Fig. 4 – Cancer-specific survival (CSS) probability within the pT3c
subcategory. Three-year CSS was 30% in patients with
supradiaphragmatic vena caval thrombus only (blue curve) and 20% in
patients with concomitant invasion of the perirenal fat (green curve).
Log-rank pooled over strata p = 0.33.
[(Fig._5)TD$FIG]
Fig. 5 – Cancer-specific survival (CSS) probability within the pT4
subcategory (log-rank pooled over strata p = 0.32). Five-year CSS was
30.9% in patients with adrenal gland invasion only (blue curve), 20% in
patients with invasion of the Gerota fascia (green curve), and 34.8% in
patients with the two concomitant features (red curve). Gerota fascia
invasion only versus adrenal gland invasion only: log-rank pairwise
p = 0.14. Concomitant Gerota fascia and adrenal gland invasion versus
adrenal gland invasion only: log-rank pairwise p = 0.47. Concomitant
Gerota fascia and adrenal gland invasion versus Gerota fascia invasion
only: log rank pairwise p = 0.53.
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same aggressive clinical behavior of those extending
beyond the Gerota fascia [12–14,16,17]. However, the
pT3a and pT3b stages both included patients with different
CSS (ie, those presenting concomitant unfavorable fea-
tures). The opportunity to stratify the outcome of patients
with locally advanced RCC taking in account the concomi-
tant presence of multiple concomitant pathologic features
had been proposed in three previous studies, all of which
aimed at improving the primary tumor classification of
locally advanced RCC [12–14]. Specifically, Thompson et al
had reported on about 700 patients treated at the Mayo
Clinic, proposing to distinguish locally advanced RCC into
five subgroups (pT3a, renal vein thrombosis only; pT3b, fat
invasion only; pT3c, renal vein thrombosis and perirenal fat
infiltration or subdiaphragmatic vena cava thrombosis
only; pT3d, subdiaphragmatic vena cava thrombosis with
perirenal fat infiltration or supradiaphragmatic inferior
vena cava thrombosis; and pT4, extension beyond the
Gerota fascia or ipsilateral adrenal invasion) [12]. However,
although all components of the proposed reclassification
were statistically significantly different from the reference
group consisting of patients with renal vein thrombosis
only after adjusting for N and M stages, the survival
probabilities of all the subgroups were clearly overlapping
in Thompson’s paper. Similarly, Ficarra et al evaluated 227
patients treated at two academic Italian centers, proposing
Table 2 – Univariable and multivariable Cox regression analyses of TNM staging system for prediction of cancer-specific mortality in 5339
patients (786 cancer-specific deaths)
Univariable analysis Multivariable analysis
Parameter HR 95% CI p value HR 95% CI p value
Age, continuous 1.02 1.01–1.02 <0.001 1.01 1–1.02 0.002
Gender 0.016 <0.001
Male 1 Reference – 1 Reference –
Female 0.8 0.7–0.9 – 0.7 0.6–0.9 –
Mode of presentation <0.001 <0.001
Incidental 1 Reference – 1 Reference –
Local symptoms 2.6 2.3–3.1 <0.001 1.4 1.2–1.7 <0.001
Systemic symptoms 6.9 5.6–8.6 <0.001 2.0 1.5–2.5 <0.001
Type of surgery <0.001 0.050
Radical nephrectomy 1 Reference – 1 Reference –
Elective partial nephrectomy 0.2 0.1–0.3 <0.001 0.6 0.5–0.9 0.019
Imperative partial nephrectomy 0.6 0.4–0.9 0.009 1.1 0.7–1.7 0.655
Histologic subtype <0.001 <0.001
Clear cell 1 Reference – 1 Reference –
Papillary 0.8 0.6–0.9 0.032 0.7 0.5–0.9 0.024
Chromophobe 0.4 0.3–0.7 <0.001 0.6 0.4–0.9 0.040
Collecting duct 4.1 2.6–6.5 <0.001 2.4 1.4–4.0 0.001
Unclassified 2.9 2.0–4.2 <0.001 1.7 1.2–2.5 0.009
Pathologic tumor size, continuous 1.2 1.1–1.2 <0.001 1.03 1.0–1.06 0.016
Pathologic T stage <0.001 <0.001
T1a 1 Reference – 1 Reference –
T1b 1.6 1.2–2.2 0.001 1.1 0.8–1.5 0.700
T2a 3.6 2.6–4.9 <0.001 1.8 1.2–2.6 0.002
T2b 7.2 5–10.3 <0.001 2.6 1.6–4.2 <0.001
T3a 8.4 6.6–10.8 <0.001 2.8 2.1–3.9 <0.001
T3b 14.2 9.9–20.6 <0.001 3.8 2.5–5.9 <0.001
T3c 36.7 21.5–63.2 <0.001 6.4 3.3–12.7 <0.001
T4 26.6 20.0–35.2 <0.001 3.1 2.1–4.7 <0.001
Pathologic N stage <0.001 <0.001
N0 1 Reference – 1 Reference –
Nx 0.6 0.5–0.7 <0.001 0.9 0.7–1.1 0.293
N1 6.9 5.3–8.9 <0.001 2.2 1.6–2.9 <0.001
N2 8.7 6.9–10.9 <0.001 2.2 1.7–2.9 <0.001
M stage <0.001 <0.001
M0 1 Reference – 1 Reference –
M+ 12.7 10.9–14.8 – 4.1 3.4–4.9 –
Fuhrman nuclear grade <0.001 <0.001
G1 1 Reference – 1 Reference –
G2 2.0 1.4–3.0 <0.001 1.6 1.01–2.4 0.047
G3 6.4 4.3–9.5 <0.001 2.7 1.7–4.1 <0.001
G4 18.0 12–26.9 <0.001 3.4 2.1–5.4 <0.001
CI = confidence interval; HR = hazard ratio.
E U R O P E A N U R O L O G Y 5 8 ( 2 0 1 0 ) 5 8 8 – 5 9 5 593
to distinguish pT3a (perirenal fat invasion or renal vein
thrombosis or thrombosis within the vena cava below the
diaphragm), pT3b (renal vein thrombosis or thrombosis
within the vena cava below the diaphragm associated with
perirenal fat invasion), and pT4 (adrenal gland invasion or
Gerota fascia invasion or thrombosis within the vena cava
above the diaphragm) [13]. That proposal was further
updated in a larger analysis involving about 2000 patients
with pT3–pT4 RCC treated at 12 European centers. The data
from that analysis suggested the possibility of stratifying
locally advanced RCC as follows: pT3a, renal vein or
infradiaphragmatic vena caval thrombosis, or perirenal
fat invasion; pT3b, ipsilateral adrenal direct invasion or
venous thrombosis plus perirenal fat invasion; pT4, venous
thrombosis and ipsilateral adrenal direct invasion, supra-
diaphragmatic vena caval thrombosis or tumors extending
beyond Gerota fascia [14]. However, none of these
proposals for reclassification of locally advanced RCC were
included in the new staging system, and the prognostic role
of the concomitant presence of adverse pathologic features
(eg, perirenal fat involvement and extent of tumor
thrombosis) was not taken in account.
There are several limitations to our study. First and
foremost are those inherent to any retrospective analysis. In
addition, the population in this study underwent surgery in
multiple centers, and specimens were evaluated by multi-
ple pathologists without slide review. However, all
surgeons operated at selected centers with significant
experience in RCC management, which might increase the
external validity of the data as compared with the single-
center, single-surgeon setting. Similarly, although it may be
preferable for a single pathologist specialized in genitouri-
nary pathology to review each specimen, the present study
reflects a real-world scenario. Moreover, although the series
was very large, the number of pT2b, pT3b, pT3c, and pT4
cases was quite low, which might have resulted in some
underpowered statistical analyses. This low number par-
tially reflects the stage’s distribution of RCC at surgery but is
significantly affected by the excessive tendency to sub-
stratify in the current TNM staging system, which includes
four substages for localized RCC and four for locally
advanced RCC. Finally, most of the patients who had a
recurrence of disease in the present cohort did not have
access to targeted therapies and were treated before the
development of tyrosine kinase and mammalian target of
rapamycin inhibitors.
5. Conclusions
In the present series, the recently released seventh edition
of the primary tumor staging system for RCC was a powerful
independent predictor of CSS. However, some of the
substages identified by the classification had overlapping
prognoses, whereas other substages included patients with
heterogeneous outcomes. Although in the past few years
several reports have highlighted the need to change the
TNM classification both for localized and locally advanced
stages, only a few modifications have been included in the
latest version of the TNM.
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